Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Did FDA's Pain Med Warning Scare Shionogi Away From Victory?

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal to buy Victory, maker of acetaminophen-combo products, disappears into thin air soon after liver injury scare.

You may also be interested in...



FDA Panel Supports Lower Acetaminophen Dose But Spares Combo Products

In what could be a major blow to manufacturers, acetaminophen sold in 500 mg tablets will come off the OTC market if FDA follows a joint advisory committee's recommendations, but the industry may be spared the additional pain of losing combination products that include acetaminophen and other ingredients.

Deals Shaping the Medical Industry (06/2009)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.

Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition

Shionogi offers strong pipeline, Sciele brings 770-strong sales force to Japan-U.S. pairing.

Related Content

Topics

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel